HC Wainwright Has Negative Estimate for MLTX FY2026 Earnings

MoonLake Immunotherapeutics (NASDAQ:MLTX) – Analysts at HC Wainwright reduced their FY2026 earnings per share (EPS) estimates for shares of MoonLake Immunotherapeutics in a report released on Monday, November 9th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings per share of ($3.58) for the year, down from their previous forecast of ($3.17). HC Wainwright currently has a “Buy” rating and a $50.00 price objective on the stock. The consensus estimate for MoonLake Immunotherapeutics’ current full-year earnings is ($3.45) per share. HC Wainwright also issued estimates for MoonLake Immunotherapeutics’ Q4 2026 earnings at ($0.84) EPS, Q1 2027 earnings at ($0.79) EPS, Q2 2027 earnings at ($0.77) EPS, Q3 2027 earnings at ($0.82) EPS, Q4 2027 earnings at ($0.63) EPS and FY2027 earnings at ($3.01) EPS.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last issued its quarterly earnings results on Wednesday, November 4th. The company reported ($0.93) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.10).

A number of other research firms have also recently commented on MLTX. Chardan Capital began coverage on shares of MoonLake Immunotherapeutics in a research note on Friday, November 6th. They issued a “buy” rating and a $57.00 price target for the company. Wall Street Zen downgraded shares of MoonLake Immunotherapeutics from a “sell” rating to a “strong sell” rating in a report on Sunday, September 27th. Weiss Ratings raised shares of MoonLake Immunotherapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, August 21st. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of MoonLake Immunotherapeutics in a research report on Wednesday, September 16th. Ten analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, MoonLake Immunotherapeutics has a consensus rating of “Moderate Buy” and an average target price of $31.09.

MoonLake Immunotherapeutics Trading Down 0.5%

Shares of MoonLake Immunotherapeutics stock opened at $12.56 on Wednesday. MoonLake Immunotherapeutics has a 1 year low of $9.46 and a 1 year high of $23.29. The firm has a market cap of $1.07 billion, a PE ratio of -3.42 and a beta of 1.14. The company has a debt-to-equity ratio of 0.26, a current ratio of 9.13 and a quick ratio of 9.13. The company has a 50 day simple moving average of $12.01 and a two-hundred day simple moving average of $16.29.

Institutional Trading of MoonLake Immunotherapeutics

A number of hedge funds have recently bought and sold shares of MLTX. Janus Henderson Group PLC boosted its stake in MoonLake Immunotherapeutics by 64.7% in the first quarter. Janus Henderson Group PLC now owns 3,451,628 shares of the company’s stock worth $64,304,000 after buying an additional 1,355,640 shares in the last quarter. Weiss Asset Management LP boosted its stake in shares of MoonLake Immunotherapeutics by 413.1% in the 1st quarter. Weiss Asset Management LP now owns 1,708,328 shares of the company’s stock valued at $31,843,000 after purchasing an additional 1,375,367 shares in the last quarter. Bank of America Corp DE boosted its stake in shares of MoonLake Immunotherapeutics by 5,255.8% in the 1st quarter. Bank of America Corp DE now owns 724,794 shares of the company’s stock valued at $13,510,000 after purchasing an additional 711,261 shares in the last quarter. Renaissance Technologies LLC boosted its stake in shares of MoonLake Immunotherapeutics by 105.8% in the 1st quarter. Renaissance Technologies LLC now owns 276,772 shares of the company’s stock valued at $5,159,000 after purchasing an additional 142,300 shares in the last quarter. Finally, Granahan Investment Management LLC grew its holdings in shares of MoonLake Immunotherapeutics by 11.2% during the 1st quarter. Granahan Investment Management LLC now owns 220,600 shares of the company’s stock valued at $4,112,000 after purchasing an additional 22,293 shares during the last quarter. Institutional investors own 93.85% of the company’s stock.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is a Switzerland-based clinical-stage biopharmaceutical company focused on developing treatments for inflammatory skin and joint diseases. The company was established in 2021 and is headquartered in Zug. Its lead investigational medicine, sonelokimab, is a nanobody designed to inhibit the inflammatory proteins IL-17A and IL-17F. MoonLake is studying the drug as a potential treatment for conditions including hidradenitis suppurativa, psoriatic arthritis and axial spondyloarthritis.